Holen Sie sich die Stockscreener-App
1.415
6.39%
0.085
Handel nachbörslich:
1.40
-0.015
-1.06%
Schlusskurs vom Vortag:
$1.33
Offen:
$1.32
24-Stunden-Volumen:
699.20K
Relative Volume:
0.59
Marktkapitalisierung:
$295.63M
Einnahmen:
$889.00K
Nettoeinkommen (Verlust:
$-156.28M
KGV:
-2.6865
EPS:
-0.5267
Netto-Cashflow:
$-150.06M
1W Leistung:
-16.27%
1M Leistung:
-12.65%
6M Leistung:
-29.95%
1J Leistung:
-40.04%
1-Tages-Spanne:
$1.31
$1.42
1-Wochen-Bereich:
$1.30
$1.68
52-Wochen-Spanne:
$1.30
$3.4799
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.415 | 277.87M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) - Seeking Alpha
What is HC Wainwright's Estimate for ProKidney Q3 Earnings? - marketbeat.com
ProKidney Corp. (PROK) Slides 9.3% to $1.46 as Key Support Level Comes into FocusVolume Breakout Ideas - dars.gov.et
Morgan Stanley (PROK) filings show ProKidney stake at 4.7% and below 5% level - Stock Titan
ProKidney FY2030 EPS Estimate Decreased by HC Wainwright - marketbeat.com
ProKidney reports larger second-quarter loss as key clinical trial expenses mount - Winston-Salem Journal
ProKidney earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProKidney earnings missed, revenue topped estimates - Investing.com
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
ProKidney completes Phase 3 PROACT 1 accelerated approval enrollment - scanx.trade
ProKidney (NASDAQ:PROK) Releases Earnings Results, Misses Estimates By $0.01 EPS - marketbeat.com
ProKidney reports Q2 revenue of $150,000 as PROACT 1 advances - Quiver Quantitative
Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise - TradingView
PROK: Completed key Phase 3 trial enrollment; cash supports operations into mid-2027 - TradingView
ProKidney Corp. (NASDAQ: PROK) warns on cash runway after $89M H1 loss - Stock Titan
ProKidney Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights - GlobeNewswire
ProKidney Corp (PROK) Stock News Today - TradingKey
ProKidney Corp. (PROK) director converts paired units into Class A stock - Stock Titan
3 Promising Penny Stocks With Market Caps Under $500M - simplywall.st
PROK Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ProKidney (PROK) to Release Quarterly Earnings on Tuesday - marketbeat.com
ProKidney Corp. Revenue Breakdown – NASDAQ:PROK - TradingView
PROK Q2'26 Earnings: revenue estimate is 186.25K USD - TradingView
ProKidney Corp (PROK) Income Statement - TradingKey
PROK|ProKidney Corp|Price:1.565|Chg%:+0.025 - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProKidney Corp (PROK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProKidney Corp (PROK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProKidney Corp (PROK) Balance Sheet - TradingKey
ProKidney Corp (PROK) Cash Flow - TradingKey
PROK|ProKidney Corp|Price:1.504|Chg%:+0.004 - TradingKey
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower Loss as Clinical Pipeline AdvancesFiscal Year Earnings - dars.gov.et
ProKidney Corp (PROK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProKidney (NASDAQ:PROK) Trading Down 0.7%Time to Sell? - marketbeat.com
ProKidney Corp. (PROK) Q1 2026 Earnings: In-Line EPS, Pre-Revenue Progress Drives Modest Stock GainROA Comparison - dars.gov.et
Meet the Biotech Stock That Rocketed 775% Higher - MSN
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProKidney Corp. Q1 2026 Earnings: Clinical-Stage Biotech Posts Narrower-Than-Expected Loss, Shares RallyEPS Revision Trend - dars.gov.et
ProKidney Corp. (PROK) Declines Sharply: Key Support Level Under ScrutinyMFI Overbought - dars.gov.et
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrowed Loss Slightly Beats Estimates Amid Pipeline Focus - dars.gov.et
ProKidney (NASDAQ:PROK): Can This Penny Stock Rebound? - Kalkine Media
What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite? - Kalkine Media
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEstimate Uncertainty - dars.gov.et
ProKidney (PROK) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary - Quartr
ProKidney (NASDAQ: PROK) CTO awarded 750,000 stock options at $1.89 strike - Stock Titan
July 2026 Penny Stocks With Promising Potential - simplywall.st
PROK Q1 2026 Earnings: EPS Slightly Exceeds Estimates as Clinical Progress ContinuesRevenue Guidance Range - dars.gov.et
PROKProKidney Corp Short Interest - Finviz
Is ProKidney (NASDAQ:PROK) In A Good Position To Invest In Growth? - 富途牛牛
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prokidney Corp-Aktie (PROK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director |
Nov 12 '25 |
Sale |
2.72 |
255,026 |
694,515 |
54,333 |
2.20%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):